Our current analysis of RGC integrity in the superior temporal retina indicates marked decreases in RBPMS+ RGC counts or immunoreactive area (by 47–55% in MCI and 46–50% in AD) compared to CN controls, with similar degrees of decreases observed in GCL Nissl+ neurons (by 56% in MCI and 55% in AD patients). This evidence concerns the gene RBPMS and Alzheimer disease.